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Abstract 
Aims 
Surveillance of medication use in pregnancy is essential in order to identify associations between first 
trimester medications and congenital anomalies (CAs). Medications in the same Anatomical Chemical 
Therapeutic classes may have similar effects. We aimed to use this information to improve the 
detection of potential teratogens in CA surveillance data.  
Methods 
Data on 15,058 malformed foetuses with first trimester medication exposures from 1995-2011 were 
available from EUROmediCAT, a network of European CA registries. For each medication-CA 
combination, the proportion of the CA in foetuses with the medication was compared to the 
proportion of the CA in all other foetuses in the dataset. The Australian classification system was used 
to identify “high risk” medications in order to compare two methods of controlling the false discovery 
rate (FDR): a “single” FDR applied across all combinations, and a “double” FDR incorporating groupings 
of medications.  
Results 
There were 28,765 potential combinations (523 medications x 55 CAs) for analysis. An FDR cut-off of 
50% resulted in a reasonable effective workload, for which single FDR gave rise to 8 medication signals 
(3 “high risk” medications) and double FDR 50% identified 16 signals (6 “high risk”). Over a range of 
FDR cut-offs, double FDR identified more “high risk” medications as signals, for comparable effective 
workloads. 
Conclusions 
The double FDR method appears to improve the detection of potential teratogens in comparison to 
the single FDR, while maintaining a low risk of false positives.  Use of double FDR is recommended in 
routine signal detection analyses of CA data.  
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What is already known on this subject 
 Continued post-marketing surveillance of medication safety in pregnancy is important due to 
a lack of safety information for medications taken during pregnancy. 
 EUROmediCAT performs systematic signal detection using data from population-based 
congenital anomaly registries. 
 The current EUROmediCAT method examines each medication separately, without taking 
similarities amongst medications into account.  
What this study adds 
 Information about which Anatomical Chemical Therapeutic class a medication belongs to can 
be used to improve the detection of potential teratogens in the analysis of first trimester 
exposure in foetuses with congenital anomalies.   
 Identified associations between medications and congenital anomalies require validation 
from independent data sources.  
Introduction 
The first trimester of pregnancy is an essential stage of development for the foetus, when organs 
undergo critical steps in their development and most non-inherited congenital anomalies (CAs) occur. 
Certain medications can cause CAs when taken during early pregnancy, yet exposure to prescription 
and over-the-counter medication during pregnancy is common [1, 2]. Despite this widespread use, 
information on the safety of medicines in human pregnancy is lacking, particularly for new products; 
a key reason is that pregnant women are usually exempt from pre-marketing medication safety 
studies. When a medication is licensed for marketing, little or nothing is generally known about the 
safety for its use during pregnancy. Whilst information about reproductive toxicity is sometimes 
available from animal studies, these are limited in their ability to predict risks of CA in humans [3]. As 
such, post-marketing studies and the continued surveillance of medication use in pregnancy are 
essential in order to detect new teratogens. 
EUROmediCAT is a network of European CA registries, which has developed a systematic signal 
detection method to identify medications potentially associated with an increased risk of specific CAs 
[4, 5]. This method searches thousands of medication-CA combinations to identify a small set of 
medication-CA combinations that are more likely than the other combinations to contain some true 
associations between the medications and the CAs. These combinations are called signals, and once 
identified they need to be investigated in detail [6]. In order to only identify a small set of signals a 
false discovery rate (FDR) procedure is used. The FDR is the proportion of false positive results among 
the set of all positive results, e.g. an FDR of 10% means that up to 10% of identified associations are 
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expected to be false positives. The Anatomical Therapeutic Chemical (ATC) system is used to code 
medications [6], with those in the same ATC classes often working in similar ways. However, this 
information is not incorporated in the current EUROmediCAT signal detection method, which 
examines each medication and each CA separately [5]. In this study, we aimed to refine signal 
detection methods for CA data by using a “double” FDR procedure, which takes groupings of ATC 
medications or groupings of CA into account. If similar medications are likely to have similar 
teratogenic effects or if similar anomalies are likely to be caused by the same medications, then the 
double FDR will use this information, and may be a more efficient method to identify signals compared 
to the single FDR method. The double FDR was first proposed by Mehrotra and Heyse in 2004 [7]; here 
we use an improved version of the double FDR as presented by Mehrotra and Adewale in 2012 [8]. 
Methods 
Study population  
Built on the European Surveillance of Congenital Anomalies (EUROCAT) network of population-based 
CA registries, EUROmediCAT includes registries with information on first trimester medication use. 
Consistency of inclusion criteria, data collection and recording across EUROCAT registries is monitored 
using data quality indicators [9]. EUROmediCAT data on malformed foetuses with first trimester 
medication exposures from 1995-2011 were available, for a population coverage of around 7 million 
births from 11 European countries, across 13 registries that agreed to participate in this study (Table 
1). Ethical and data access approvals were obtained for each database from the relevant governance 
infrastructures. A large proportion of this EUROmediCAT dataset has been previously analysed for 
signal detection purposes [5]. 
Congenital anomaly data 
EUROCAT registries use multiple sources of information to ascertain all CA cases, including live birth, 
foetal death and termination of pregnancy for foetal anomaly. Data is obtained through active case 
finding and voluntary reporting [10]. All EUROCAT registries use a standardised methodology, i.e. 
standard variables, definitions and coding instructions [11]. CAs are coded according to EUROCAT 
coding guide version 1.4, which uses the International Classification of Diseases (ICD) version 10 with 
the British Paediatric Association (BPA) extension. ICD10-BPA codes are used to group cases of CA into 
standard subgroups, described in detail in the EUROCAT coding guide 1.4 (http://www.eurocat-
network.eu/content/Section%203.3-%2027_Oct2016.pdf) [11]. Cases with genetic conditions 
(chromosomal anomalies, skeletal dysplasia, genetic syndromes or microdeletions) were excluded 
from this study. Foetuses with isolated congenital dislocation of the hip as their only major CA were 
also excluded, since the aetiology of this CA is mechanical. Foetuses exposed only to vitamins, minerals 
and/or folic acid were excluded. Foetuses with a congenital heart defect (CHD) but no information 
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regarding the specific type of CHD were combined into a separate subgroup (unspecified CHD, n=542) 
for analysis purposes. We performed signal detection for 55 EUROCAT CA subgroups that were 
analysed in the previous EUROmediCAT signal detection analysis, but here including two fewer CAs 
due to a more recent version of EUROCAT coding being used for the extraction of data. 
Exposure data 
Maternal medication exposure data in EUROmediCAT are obtained from prospectively recorded 
maternity records (medical files); additional data sources include general practitioner records, 
maternal interviews and infant medical records [12, 13]. Data collection and processing methods vary, 
with completeness of information and the type of medications recorded (e.g. over-the-counter, 
prescribed use and/or actual use) differing between registries [12]. Inclusion in the EUROmediCAT 
database requires first trimester exposures, defined as the first day of a woman’s last menstrual period 
to the end of her twelfth gestational week [11]. The EUROCAT coding guide instructs registries to 
calculate length of gestation by using “best estimate based on last menstrual period and/or ultrasound 
determination”. An unlimited number of exposures are recorded using the hierarchical ATC system, 
with up to 7 digits and free text information where required. Medications were analysed using 7-digit 
ATC5 codes; 5-digit ATC4 level codes were used only where a more detailed ATC5 code was 
unavailable. We were not able to differentiate between exposures to the same medication at different 
dosages since EUROmediCAT registries do not routinely include this information. ATC codes subject to 
alterations over time were identified from the WHO website [14], with older codes updated where 
available. Cases exposed exclusively to codes with less than 5 digits (not coded to at least ATC4), 
topical medications (including eye drops and other non-oral/non-IV medications) and medications 
taken in the 2nd/3rd trimester or with unknown timing were also excluded. Medications recorded in 
less than 3 foetuses were not investigated, but foetuses exposed to these medications were included 
as controls in analyses.  
Statistical analysis 
For each medication-CA combination, the proportion of CA cases in foetuses with the medication 
exposure was compared to the proportion of that CA in all other foetuses in the dataset (i.e. those 
without that specific medication, but exposed to at least one other medication). An unadjusted, one-
sided Fisher’s exact test was used. For each medication-CA combination, registries with no exposures 
and registries with no cases were excluded from that particular analysis. Outcomes were reported 
using proportional reporting ratios (PRRs) and P-values. All analyses were performed using Stata 
version 12 [15]. 
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A “single” Simes adjustment [16] across all medication-CA combinations was used to control the FDR, 
as per existing EUROmediCAT methodology [5]. We compared this to a “double” FDR procedure [8], 
incorporating an additional step to consider groupings of medications.  
The single FDR procedure is specified for 𝑚 tests and an FDR cut-off α as follows 
 Order P-values 𝑃𝑖  according to their magnitude 𝑃1 < ⋯ < 𝑃𝑚 
 Let ?̃?𝑖 denote the FDR adjusted value for 𝑃𝑖, where  
?̃?𝑚 = 𝑃𝑚 
?̃?𝑖 = 𝑚𝑖𝑛 (
𝑚
𝑖
𝑃𝑖 , ?̃?𝑖+1)    𝑓𝑜𝑟 𝑖 ≤ 𝑚 − 1 
 Null hypotheses with ?̃?𝑖 ≤  α are rejected; these combinations are the potential signals  
The double FDR is specified for 𝑖 = 1, … , 𝑛 medication groups each with 𝑔𝑖 (𝑗 = 1, … , 𝑔𝑖) medications 
as follows 
Step 1: Perform a single FDR adjustment (as above) within each group 𝑖 to get ?̃?𝑖𝑗, then let 𝑃𝑖
∗ 
denote the smallest FDR-adjusted P-value in each group  
𝑃𝑖
∗ =  min (?̃?𝑖𝑗; 1 ≤ 𝑗 ≤ 𝑔𝑖) 
Apply an FDR adjustment to the 𝑃𝑖
∗ to get the set of representative FDR-adjusted P-values ?̃?𝑖
∗, 
where 𝑃1
∗ < ⋯ < 𝑃𝑛
∗ and 
?̃?𝑛
∗ = 𝑃𝑛
∗ 
?̃?𝑖
∗ = 𝑚𝑖𝑛 (
𝑛
𝑖
𝑃𝑖
∗ , ?̃?𝑖+1
∗ )    𝑓𝑜𝑟 𝑖 ≤ 𝑛 − 1 
All groups 𝑖 where ?̃?𝑖
∗  ≤ 𝛼 are taken to the second step.  
Step 2: Let 𝐹 ≡  {𝑃𝑖𝑗 | ?̃?𝑖
∗  ≤ 𝛼 } be the family of P-values from groups flagged by ?̃?𝑖
∗ in step 1. 
Then apply a single FDR procedure across all P-values in 𝐹 such that ?̃?𝑖𝑗
(𝐹)
 is the FDR-adjusted 
P-value for all 𝑃𝑖𝑗 ∈ 𝐹. Null hypotheses are rejected for all tests where ?̃?𝑖𝑗
(𝐹)
≤ 𝛼; these 
combinations are the potential signals. 
The FDR cut-off is defined for a pre-specified proportion α between 0 and 1; e.g. α = 0.1 corresponds 
to an FDR of 10%, meaning that up to 10% of combinations identified as signals are expected to be 
false positives. The overall FDR level for double FDR is at most 𝛼 at the group level no matter how 
many groups contain at least one true signal, hence it may be possible that the overall FDR exceeds 
𝛼 in some scenarios [8].  A lack of low powered associations violates the underlying assumptions of a 
multiple testing procedure by markedly shifting the distribution of P-values towards zero; associations 
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for combinations with less than 3 exposed cases were therefore retained in the multiple testing 
procedures, but were not flagged as signals for further consideration. 
Grouping of medication-anomaly combinations  
Medications were grouped according to pharmacological subgroups using 4-digit ATC3 codes (n=116 
groups). ATC4 (chemical subgroup) codes were considered too detailed for grouping purposes, 
resulting in a large number of groups (n=244). ATC2 (therapeutic main group) levels would provide a 
smaller number of groups (n=61), but these would include a range of medications and were 
considered too heterogeneous for grouping purposes. Both ATC2 and ATC4 were considered in 
sensitivity analysis. Certain CAs are thought to be more sensitive (compared to other types of CAs) to 
medications in general, and it may be likely that a number of CAs have no signals at all. We therefore 
also considered grouping medication-CA combinations by CA. 
Evaluation and comparison of signal detection methods  
The Australian government department of health provides a database of recorded pregnancy related 
risks associated with medicines [17]. All medications are divided into five main lettered categories: 
category A medications are considered safe for use during pregnancy; category B have not shown 
evidence of harmful effects to human foetuses; category C may carry harmful effects to human 
foetuses, without evidence of causing CAs; categories D and X have evidence of moderate to high 
teratogenic risk. Specific CAs are not identified. This database was used to independently identify 
medications for which there has been evidence of high teratogenic risk by grouping medications as 
“high risk” (categories D and X) or “low risk” (categories A, B or C). Medications that could not be 
mapped to a risk category (i.e. that were not present) in this database were grouped as “unclassified 
risk”. Medication names were matched to EUROmediCAT data using substance names. The total 
number of “high risk” medications identified by single and double FDR were compared, and the 
proportion of all the “high risk” medications in the data that were identified as signals was calculated. 
This was defined as  
𝐈𝐝𝐞𝐧𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐫𝐚𝐭𝐞 =
Number of "high risk" medications identified as signals
Total number of "high risk" medications in the data
 
The total number of medications in the set of signals (the “effective workload”) identified by each 
method was also considered, since each medication signal requires further investigation regardless of 
the number of different CAs it may be associated with.  
Results 
Description of signal detection dataset 
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A total of 31,197 foetuses with at least one first trimester medication exposure and a major CA born 
from 1995-2011 were extracted from the EUROmediCAT central database for 13 registries. Of these, 
905 foetuses with isolated congenital dislocation of the hip, 1,219 with no ATC4 or ATC5 exposures 
recorded and 452 with only topical medication exposures were excluded, leaving 28,621 foetuses with 
valid medication exposures (Table 1). Foetuses with exposures only occurring outside the first 
trimester of pregnancy (n=1,490) or with unknown timing (n=12,073) were further excluded, leaving 
15,058 foetuses for analysis. Some registries had considerable data loss where it was not possible to 
verify when the reported medications had been taken (Table 1), and this has been discussed previously 
[5]. However, the distribution of types of CA were similar for those pregnancies included and excluded 
due to unknown timing, suggesting that cases remaining in the dataset for these registries aren’t 
prone to selection biases in this respect.  
On average, there were 1.6 recorded ATC non-topical medication exposures per pregnancy, ranging 
from one (in 65% of cases) up to 16 (one case). The total number of exposures to medications 
appearing at least 3 times in the dataset was 22,624; this included 523 ATC medications, of which 39 
(7.5%) were coded only to ATC4. With 55 CAs for analysis, this gave 28,765 potential medication-CA 
combinations. Using ATC3 grouping resulted in 116 distinct groups with an average of 9 (range 1-20) 
unique medications and 487 (range 53-1,086) medication-CA combinations per group. 
Of the 523 medications in the data, 297 (57%) were “low risk”, 44 (8.4%) were “high risk” and 182 
(35%) had “unclassified risk” according to the Australian risk categorisation database. Three 
medications mapped to a code in both the “low risk” and “high risk” group depending on their dosage. 
As there is no information on dosage in EUROmediCAT data, these medications weren’t assigned to 
either risk category but were instead coded as “unclassified risk”. Of the 116 ATC3 groups, 94 (81%) 
contained no “high risk” medications, 13 (11%) contained only one, and 9 (8%) groups contained two 
or more “high risk” medications. 
Comparison of single and double FDR procedures to adjust for multiple testing 
There were no cases for 369 specific medication-CA combinations, hence Fisher’s exact test was 
performed for 28,396 combinations. Figure 1 is a smileplot [18], plotting the PRR against the P-value 
for each combination. Without adjustment for multiple testing, 670 combinations were significant at 
the conventional 5% level (points above the lower dashed line in Figure 1). For a cut-off of 50%, single 
FDR resulted in 10 medication-CA combinations being identified as signals (diamond symbols in Figure 
1), involving 8 medications (1 medication had signals for 3 CAs). Double FDR 50% resulted in 25 
medication-CA combinations being identified as signals (+ symbols in Figure 1), involving 16 
medications (4 medications had signals for 2 CAs, 1 medication for 3 CAs and 1 medication for 4 CAs) 
in 5 ATC3 groups. 
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Double FDR 50% signals included 5 antiepileptic medications (4 “high risk”, 1 “low risk”), 4 insulin 
medications (2 “low risk”, 2 “unclassified risk”), 3 sex hormones (1 “high risk”, 2 “unclassified risk”), 2 
antiasthmatic medications (both “low risk”) one “unclassified risk” gynaecological medication and one 
“high risk” medication for acid related disorders. Single FDR 50% identified only 7 of these medication 
signals over 10 combinations, including 2 of the antiepileptics (both “high risk”), 2 antiasthmatics (both 
“low risk”), one “unclassified risk” insulin-related medication and one “unclassified risk” sex hormone. 
Single FDR 50% also identified one further signal for a “low risk” anxiolytic medication, which was not 
a signal using double FDR 50% and was in an ATC3 group including 8 other medications that were not 
signals using either method.   
Figure 2 presents the number of signals in each risk category using ATC3 groupings for single and 
double FDR across a range of cut-offs from 5-50%. Higher cut-offs resulted in a greater number of 
signals being identified for both methods. A maximum of 3 “high risk” signals were identified by single 
FDR for any cut-off from 15-50%. Only one additional “low risk” medication was identified as a signal 
for an FDR cut-off of 35% and above. Six “high risk” medications were identified by double FDR 30%, 
above which level only one further (“low risk”) medication signal was identified. The proportion of 
signals that were “high risk” was highest for double FDR at a cut-off of 10% or less; above this threshold 
the single and double FDR had similar proportions of “high risk” signals.  
Figure 3 shows the identification rate for single and double FDR with cut-offs from 5-50%. Double FDR 
identified more of the “high risk” medications than single FDR, for a range of FDR cut-offs and 
comparable effective workloads (the number of medications identified as signals).  
Sensitivity analyses 
FDR procedures were repeated using ATC2 and ATC4 codes and CAs to group medication-CA 
combinations. Grouping by ATC2 provided 61 groups with an average of 20 (range 1-54) medications 
per group. ATC4 gave 244 groups, with an average of 3 (range 1-8) medications per group. Both these 
groupings resulted in similar or lower effective workloads across the different levels of FDR cut-off; 
however, the number and proportion of “high risk” medications detected was generally lower 
compared to ATC3 groupings. For FDR 25%, for example, ATC3 groupings identified a 11 medication 
signals of which 5 were “high risk”, compared to 12 (5 “high risk”) and 6 (2 “high risk”) for ATC2 and 
ATC4 groupings, respectively. Grouping of medication-CA combinations by the 55 CAs an average of 
518 (range 325-523) unique medication-CA combinations per group; this resulted in a greater number 
of signals across all levels of FDR cut-off, with no increase in the number of “high risk” medications 
identified. This might be influenced by the use of a risk classification system to judge the methods, 
since these are not specific to the type of CA. Overall, however, grouping by ATC2, ATC4 or by CA did 
not show an improvement over ATC3 grouping. 
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Of 523 medications in the analysis, 35% had “unclassified risk” (not present in the Australian 
classification system database). Sensitivity analyses were conducted to assess the effect of a number 
of hypothetical situations. Firstly, medications without a risk category were assumed to either be all 
“high risk” or all “low risk”, representing the two most extreme situations. We also considered the 
effect of assuming that a medication with “unclassified risk” was “high risk” if there was at least one 
other “high risk” medication in that group, and “low risk” if all medications in the same group had 
“low” or “unclassified risk”. For these three situations, comparisons between single and double FDR 
were the same as described previously, and conclusions remained unchanged (data not shown).  
Discussion 
We compared two FDR procedures for use in EUROmediCAT’s signal detection process to assess 
whether the FDR multiple testing adjustment could be improved by incorporating medication 
groupings. The double FDR identified more “high risk” medications as signals than the currently used 
single FDR method, for a range of FDR cut-offs and comparable resulting workloads. Using double FDR 
a cut-off level of 50% was judged appropriate, as it resulted in a reasonable effective workload (16 
medication signals over 25 combinations) requiring follow up. The only medication that was a signal 
using single but not double FDR was in the “low risk” category. All but one of the 16 additional signals 
from double FDR were in ATC3 groups including at least one other signal, highlighting how the double 
FDR picks up more signals in groups where there are other (stronger) signals.  
Results were also compared to those from the previous EUROmediCAT signal detection analysis (using 
single FDR with a 50% cut-off [5]), for which the dataset differed by omission of two registries and 
inclusion of an additional year of data for another two registries. Of the 26 combinations identified as 
signals in the present analysis, 20 were signals in the previous EUROmediCAT analysis. Combinations 
that were signals here but not in the previous analysis (where their FDR-adjusted P-values did not 
reach statistical significance using single FDR) included antiepileptic medications, which are well-
established as being a teratogenic group of medications [19-21], and progesterone sex hormones, 
which have been previously linked to an increased risk of hypospadias [22] and CHDs [23]. All signals 
identified in this study have been reported previously in the literature; however, as the EUROmediCAT 
database increases in size annually, future analyses are expected to identify new associations, 
particularly for newer medications. The identification of signals using double FDR is more powerful 
than single FDR methodology, and will provide additional independent information to confirm the 
results of hypothesis driven studies for specific types of medications, as well as evidence to perform 
new hypothesis driven studies. 
Statistical considerations 
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The choice of FDR cut-off level should balance the proportion of false negative and false positive 
associations. If this is set too high, the resulting workload for follow up of associations may be 
impractical, and there is potential for unwarranted anxiety to pregnant women if false positive 
associations are reported. A low FDR cut-off, conversely, could miss important signals and result in 
delay of detecting such teratogens until more data (i.e. more exposures to harmful medications) are 
available. The FDR 50% used here might be considered a higher than acceptable rate of likely false 
positives, but when considering this in contrast to a lack of any adjustment for multiple testing (where 
the FDR approaches 100%), a cut-off of 50% is an improvement. The choice of FDR cut-off should be 
re-evaluated frequently, and in practice should depend on resources available for follow-up of signals. 
One-sided tests are used for CA signal detection as only foetuses with a CA are included; if a 
medication reduces the risk of a CA there will, by definition, be fewer cases in the study population 
and therefore a low power to detect preventive medications. Two combinations indicated preventive 
associations using both FDR procedures; these associations are likely due to chance or biases occurring 
from the study design (as controls all have at least one CA and one medication exposure). 
Furthermore, the comparison is to other CAs and medications in the database, hence preventive 
associations would not imply that the overall risk of a CA is likely to be lower. Adjustment for registry 
was not done as numbers were already small for the majority of combinations. 
Evaluation of signal detection methods  
Evaluation of signal detection methods in CA data is difficult due to the lack of a “gold standard” to 
classify risks for medications in pregnancy according to CAs. A definitive measure of how many 
teratogens are missed by a signal detection method, and possible reasons for such lack of detection, 
cannot therefore be obtained. To evaluate EUROmediCAT’s signal detection process we used the 
Australian classification system to assign risk categories to medications. Two important limitations of 
this risk classification are pertinent here; firstly, there was no available classification of pregnancy-
related risk for around a third of medications in the EUROmediCAT database. It might have been 
possible to garner further information on some of these unclassified medications by also using the 
Swedish and US risk classification systems, as done in a previous web-based study of medication safety 
of in Europe [24]. However, after including information from all three classification systems in their 
study, 23.2% of medications still remained unclassified [24], indicating that only a relatively small 
improvement would be made by including additional information from these other databases. We 
therefore considered the use of one database sufficient for our main purpose of directly comparing 
the FDR methods. Secondly, an important limitation of these risk classification systems in general is 
that specific CAs are not identified for “high risk” medications. However, the teratogenic risk of a 
medication is almost always specific to one (or more) particular CA(s), rather than an increased risk of 
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malformations in general [25]. The identification rate used in this study does not differentiate 
between a medication associated with only one CA and one associated with a number of CAs.  
Two of 5 “low risk” signals identified using double FDR with a 50% cut-off were insulin medications. It 
is not surprising to find the insulin medications in the low risk category according to the Australian 
classification system because although the association between insulin medications and CHDs is well 
documented, this is thought to be a result of the fact that the mother has diabetes rather than the 
insulin medications themselves [26-28]. This example of potential confounding by indication highlights 
that signal detection cannot distinguish between cause and effect, and emphasises the importance of 
further evaluating signals from a medical and biological perspective. The number of combinations 
identified as “high risk” may be overestimated, since categorisations are specific only to the 
medications and not the type of CA. Conversely, medications classified as B or C in the Australian 
database may be given their classification due to a lack of power with information available at the 
time of categorisation, and as such we cannot definitively say that these medications are known to be 
“low risk”. Due to these issues, the Australian categorisation system is not as precise as would be ideal 
for use as a “gold standard” in classifying teratogenic risk. However, the aim of this study was to 
directly compare the single and double FDR, and each procedure should have the same lack of data 
and power for known teratogens. We cannot provide an absolute measure of how good either method 
is for two main reasons. Firstly, there is a lack of a “gold standard”. Secondly, the number of women 
exposed to well-established teratogens (such as thalidomide or isotretinoin) during pregnancy is now 
very low due to their known risks, hence the power to detect signals for such medications in more 
recent data is low. It is therefore important to adopt more efficient methods of signal detection than 
are currently being used, rather than delay adoption due to a lack of evidence based on relatively low 
overall detection rates across the methods.   
Strengths and weaknesses 
A major strength of EUROmediCAT data is the detailed and standardised coding of CAs across registries 
[13], combined with detailed information regarding first trimester medication exposures. Good 
agreement between the medication actually used and that recorded in one EUROmediCAT registry 
has also been previously demonstrated [29]. Whilst there are variations across the registries in the 
way data regarding maternal medication use is collected, and in the quality and completeness of these 
data, there is no reason to believe that either the single FDR or the double FDR method will be more 
or less robust to such variations between registries. A potential weakness of EUROmediCAT data is 
known under ascertainment of some medications [12, 30], which may reduce the sensitivity of signal 
detection analyses. Another important limitation is the lack of information regarding the dosage of 
medication exposures, which is particularly relevant as medications in different dosages can have 
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different teratogenic effects. Timing of exposures could not be confirmed in a number of cases (a high 
proportion for the Polish registries), resulting in a loss of power and a source of potential bias. After 
data cleaning, all included cases were supposedly confirmed first trimester exposures, however it is 
not possible to know that the mothers took the medication during the critical period for development 
of each specific CA, particularly since these can differ according to the type of CA [31]. In these 
analyses, the large number of statistical tests involving very small numbers of exposures prohibits 
accurate adjustment for potential confounders, therefore multiple comparisons procedures are 
performed on unadjusted results. Nonetheless, heterogeneity between registries is considered in the 
next stage of the signal detection process; the first EUROmediCAT signal detection analysis was 
published alongside an accompanying paper that evaluated identiﬁed signals in detail, considering, 
amongst other factors: heterogeneity between registries, registry-specific effects, and potential 
confounding by indication or by co-exposure [32]. An advantage of case-malformed control studies is 
that some biases associated with the use of a healthy control population (e.g. recall and recording 
biases) are likely to be minimised. On the other hand, this type of study cannot produce medication 
exposure risk estimates for CAs compared to healthy (i.e. non-exposed and non-malformed) controls 
[33]; evidence of an increased risk of any CA in this study is relative only to the risks associated with 
other CAs.  
Conclusion 
The double FDR identified a greater number and proportion of “high risk” medications as signals than 
the currently used single FDR, for a range of FDR cut-offs and comparable resulting workloads. We 
therefore recommend that double FDR be used in routine signal detection analyses of CA data. This 
may help identify potentially teratogenic medications that could be missed by the existing single FDR 
procedure, whilst retaining an acceptable level of false positive associations. Signal detection analyses 
of CA data must continue to be accompanied by detailed follow up of any new potential signals 
identified and timely dissemination of results; together, this will help patients make appropriate 
decisions to balance any risks and benefits of medication use during their pregnancy, based on the 
most up-to-date information available. 
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Table 1. Description of data from 13 EUROmediCAT registries for the comparison of false discovery rate methods in the analysis of safety of medication use 
during first trimester of pregnancy 
EUROCAT Registry 
Birth years 
included 
Foetuses with 
CAs and at 
least one valid 
exposure 
Foetuses with CAs 
following data 
cleaning by timing 
of exposure a 
Data loss 
by data 
cleaning 
(%) a 
Total eligible ATC 
coded exposures 
Total ATC codes 
excluding those 
with <3 exposures 
Average ATC coded 
medication 
exposures per 
pregnancy 
Belgium, Antwerp 1997-2011 349 347 1 508 478 1.46 
Croatia, Zagreb 1995-2011 198 190 2 243 218 1.28 
Denmark, Odense 1995-2011 240 240 0 367 346 1.53 
France, Paris 2001-2011 658 658 0 970 897 1.47 
Italy, Emilia Romagna b, c 1995-2011 2,350 2,349 0 3,860 3,736 1.64 
Italy, Tuscany 1995-2011 1,083 1,033 4 1,417 1,352 1.37 
Malta 1996-2011 306 305 0 461 453 1.51 
Netherlands, North Netherlands 1995-2011 2,451 1,848 25 3,133 2,933 1.70 
Norway 2005-2010 3,051 3,051 0 5,535 5,481 1.81 
Poland, Wielkopolska 1999-2011 3,180 469 85 640 632 1.36 
Poland (excluding Wielkopolska) 1999-2010 12,389 2,214 82 2,788 2,741 1.26 
Switzerland, Vaud 1997-2011 309 297 1 458 433 1.54 
UK, Wales 1998-2011 2,057 2,057 0 3,030 2,924 1.47 
Total 1995-2011 28,621 15,058 47 23,410 22,624 1.55 
a After exclusion of CA registrations with only medication exposures of unknown timing 
b During the period 1995 to 2004 Emilia Romagna database had space for only 5 medications to be recorded 
c Terminations of pregnancy for foetal anomaly were excluded from the Emilia Romagna registry as information on medications is only available for live and still births 
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Figure 1. Smileplot highlighting signals identified from 28,396 medication-CA combinations by single 
and double FDR procedures, using a cut-off of 50% and ATC3 grouping (P-values truncated at 1.0E-10) 
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Figure 2. Effective workload and the number of medication signals in each risk category as identified 
by the Australian risk categorisation system database for single and double FDR, at FDR cut-offs 
ranging from 5% to 50% 
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Figure 3. Proportion of “high risk” medications in the EUROmediCAT signal detection dataset that 
were identified as signals (identification rate) against the total number of medication signals (effective 
workload) for single and double FDR, with each point corresponding to a level of FDR cut-off ranging 
from 5% to 50% 
 
